| Literature DB >> 27188322 |
Benjamí Oller-Salvia1, Macarena Sánchez-Navarro1, Ernest Giralt2, Meritxell Teixidó1.
Abstract
Brain delivery is one of the major challenges in drug development because of the high number of patients suffering from neural diseases and the low efficiency of the treatments available. Although the blood-brain barrier (BBB) prevents most drugs from reaching their targets, molecular vectors - known as BBB shuttles - offer great promise to safely overcome this formidable obstacle. In recent years, peptide shuttles have received growing attention because of their lower cost, reduced immunogenicity, and higher chemical versatility than traditional Trojan horse antibodies and other proteins.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27188322 DOI： 10.1039/c6cs00076b
Source DB: PubMed Journal: Chem Soc Rev ISSN： 0306-0012 Impact factor: 54.564